Skip to content
Screener

Tandem Diabetes Care TNDM Investing Cash Flow

Investing Cash Flow at other companies

Insulet logo
InsuletPODD
-$37.4M-60.5%
Medtronic logo
MedtronicMDT
-$917M-87.1%
Beta Bionics logo
Beta BionicsBBNX
$26.93M
Embecta Corp. logo
Embecta Corp.EMBC
-$129.5M-32,275%
AdaptHealth logo
AdaptHealthAHCO
-$204.46M-114%
InfuSystem Holdings logo
InfuSystem HoldingsINFU
-$1.26M+52.6%

Other financials

Income statement

See full
Revenue$254.6M+5.8%
Gross profit$144.8M+15.0%
Operating income-$13.8M+73.4%
Net income-$21.2M+59.6%
EPS (diluted)-$0.31+60.3%

Balance sheet

See full
Cash & equivalents$62.8M-2.0%
Total debt$739.3M+64.6%
Total equity$130.4M-2.2%
Total assets$1.2B+31.8%

Cash flow

See full
Operating cash flow-$34.6M-265%
CapEx$4.1M-34.7%
Free cash flow-$38.7M-146%

Valuation

See full
Market cap$1.56B+128%
Enterprise value$2.23B+109%
P/S1.5×+0.8×

Profitability

See full
Gross margin56%+3.5pp
Operating margin-4.4%-1.9pp
Net margin-6.1%-2.5pp
FCF margin-0.8%-0.4pp

Returns & leverage

See full
Return on equity-48%-17.5pp
Debt / equity5.7×+2.3×
Current ratio3.2×+0.7×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Tandem Diabetes Care’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001438133-26-000125
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Purchases of property and equipment(10,318)(9,171)
Acquisition of in-process research and development(43,464)
Purchases of equity investments, strategic investments, and intangible assets(81,427)
Net cash provided by (used in) investing activities(282,784)67,316
Financing Activities
Proceeds from issuance of convertible senior notes due 2032, net of $8,843 debt issuance costs291,157
Principal payments on convertible senior notes due 2025(40,760)
Payment for capped call transactions related to convertible senior notes due 2032(15,300)

Item 1. Financial Statements.

FAQ

What is Tandem Diabetes Care's investing cash flow?
Tandem Diabetes Care (TNDM) reported investing cash flow of -$87.34M in Q2 2026.
How has Tandem Diabetes Care's investing cash flow changed year-over-year?
Tandem Diabetes Care's investing cash flow decreased by 250.2% year-over-year, from $58.13M to -$87.34M.
What is the long-term trend for Tandem Diabetes Care's investing cash flow?
Over 2 years (2021 to 2023), Tandem Diabetes Care's investing cash flow has grown at a -30.1% compound annual growth rate (CAGR), from -$186.88M to -$91.44M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Tandem Diabetes Care's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude